Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Apr-Jun;37(2):278-80.
doi: 10.1080/08897077.2016.1138919.

A delayed injection-site reaction in a patient receiving extended-release naltrexone

Keith Ahamad  1   2   3 , P Todd Korthuis  4   5 , Paula J Lum  6 , Cheyenne Johnson  1 , Evan Wood  1   7
Affiliations
Case Reports

A delayed injection-site reaction in a patient receiving extended-release naltrexone

Keith Ahamad et al. Subst Abus. 2016 Apr-Jun.

Abstract

Background: Pharmacotherapy, such as oral naltrexone, has proven effective in treating alcohol use disorder, although medication adherence has presented challenges. Although a formulation of extended-release naltrexone for intramuscular injection has been developed to counter daily adherence issues, injection-site reactions can occur within days of depot injection.

Case: The authors report a case of an individual with alcohol use disorder who had a previously undescribed delayed injection-site reaction that occurred 11 days after injection. Subsequent challenge with the medication resulted in recurrence of the reaction.

Discussion: Although extended-release naltrexone is generally well tolerated, injection-site reactions can complicate treatment and can appear more than 10 days after medication administration.

Keywords: Alcohol use disorder; extended-release naltrexone; injection-site reaction.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Bouchery EE, Harwood HJ, Sacks JJ, Simon CJ, Brewer RD. Economic costs of excessive alcohol consumption in the U.S., 2006. Am J Prev Med. 2011;41:516–524. - PubMed
    1. Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311:1889–1900. - PubMed
    1. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful? Addiction. 2013;108:275–293. - PMC - PubMed
    1. Swift R, Oslin DW, Alexander M, Forman R. Adherence Monitoring in Naltrexone Pharmacotherapy Trials: A Systematic Review. Journal of studies on alcohol and drugs. 2011 Nov;72(6):1012–8. - PMC - PubMed
    1. Warren KR, Hewitt BG. NIAAA: Advancing alcohol research for 40 years. Alcohol Health & Research World. 2010 Jan 1;33(1):5. - PMC - PubMed

Publication types

MeSH terms